New imaging agent targets LRRC15 to sharpen cancer diagnosis
NCT ID NCT07651020
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a special SPECT imaging agent that seeks out a protein called LRRC15, found on many aggressive cancers like pancreatic, breast, lung, and brain tumors. The goal is to see if this scan can help doctors diagnose and stage these cancers more accurately. Healthy volunteers and people with suspected or confirmed LRRC15-positive cancers will receive the imaging agent and undergo a SPECT/CT scan.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LRRC15-targeted SPECT radiotracer
- What this could lead to
- If successful, this imaging method could improve cancer diagnosis and staging, helping doctors choose better treatments.
- What could go wrong
- This is a very early, small study with only one participant, so results may not apply broadly. The imaging agent's safety and accuracy are still being tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wuhan Union Hospital, China
Wuhan, Hubei, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a plasma beam stop colon polyps from coming back?
- Can a simple CT scan catch lung cancer earlier in kuwait?
- A stitch in time: could a device make abdominal closure safer?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts